Importing cosmetics into the United States has become considerably more complex than simply classifying products under the correct tariff code and paying the applicable import duties. Today, cosmetic imports are regulated through two interconnected frameworks. The U.S. Food and Drug Administration (FDA) oversees product safety, facility registration, product listing, labeling, and post-market compliance under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as amended by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). At the same time, U.S. Customs and Border Protection (CBP) is responsible for customs classification, admissibility, tariff collection, country-of-origin verification, and enforcement at U.S. ports of entry. Both agencies have distinct responsibilities, and importers must satisfy the requirements of each to successfully enter the U.S. market. 

MoCRA fundamentally changed the regulatory landscape for cosmetics. The legislation introduced mandatory facility registration, cosmetic product listing, safety substantiation, serious adverse event reporting, and expanded FDA enforcement authority. These obligations now sit alongside existing customs requirements such as HTSUS classification, customs valuation, and import documentation. Businesses that overlook either side of the regulatory framework risk shipment delays, product detention, or enforcement action even if every customs duty has been paid correctly. 

This guide focuses specifically on commercial imports of cosmetics and personal care products intended for sale in the United States. Whether you are an international beauty brand launching in the U.S., a distributor importing an overseas product line, an Amazon seller sourcing private-label cosmetics, or a retailer expanding your supplier network, understanding how FDA and CBP requirements work together is essential. Throughout this guide, we bridge the gap between regulatory guidance that concentrates on MoCRA and customs guidance that focuses primarily on border clearance, giving importers a complete operational picture of bringing cosmetic products into the U.S. market. 

What Counts as a Cosmetic Under U.S. Federal Law

Before determining whether a facility must register, a product must be listed, or customs documentation must be prepared, businesses first need to establish whether their product legally qualifies as a cosmetic under U.S. law. This classification determines which FDA requirements apply and whether the product may instead fall under an entirely different regulatory framework.

The FD&C Act Section 201(i) Definition

The legal definition of a cosmetic is established under Section 201(i) of the Federal Food, Drug, and Cosmetic Act. According to the statute, a cosmetic is any article intended to be rubbed, poured, sprinkled, sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering appearance. 

Unlike some jurisdictions that classify products primarily according to their ingredients, the FDA focuses heavily on intended use. Product claims, labeling, advertising, website content, instructions for use, and consumer perception all contribute to determining how the FDA regulates a product. Two formulations containing nearly identical ingredients may therefore be regulated differently if one is marketed solely to improve appearance while the other claims to treat or prevent a medical condition. 

What FDA Includes as Cosmetics

The FDA’s cosmetic definition covers a broad range of beauty and personal care products commonly sold through retail stores, e-commerce platforms, salons, and specialty beauty outlets. Examples include facial cleansers, moisturizers, foundations, lipsticks, eye makeup, perfumes, body lotions, shampoos marketed solely for cosmetic purposes, conditioners, styling products, nail polish, bath preparations, and deodorants that do not make therapeutic claims. 

From a customs perspective, most of these products are classified under HTSUS Chapter 33, although certain soaps and cleansing preparations may instead fall under Chapter 34. Proper tariff classification affects duty rates, customs declarations, and the applicability of trade programs such as the United States-Mexico-Canada Agreement (USMCA). Importers should therefore evaluate both FDA product classification and customs classification before arranging shipment. 

The Cosmetic-Drug Boundary

One of the most challenging aspects of U.S. cosmetic regulation is distinguishing between cosmetics and drugs. The determining factor is not simply how a product looks or where it is sold, but what the manufacturer claims the product does.

A moisturizer promoted to soften or beautify the skin generally remains a cosmetic. However, if that same product claims to repair damaged skin, stimulate collagen production, treat eczema, eliminate wrinkles by changing skin structure, or otherwise affect the body’s structure or function, the FDA may regulate it as a drug instead. The same principle applies to promotional material published on company websites, social media, online marketplaces, and product packaging. 

Some products may also have dual status, meaning they are regulated as both cosmetics and drugs. In such cases, businesses must comply with the legal requirements applicable to both categories before products can be lawfully marketed in the United States. 

Products That Look Like Cosmetics but Are Regulated as Drugs

Several products commonly found in the personal care aisle are regulated as over-the-counter (OTC) drugs rather than conventional cosmetics because of their intended use. These include sunscreens, anti-dandruff shampoos, antiperspirants, fluoride toothpaste, and certain anti-aging products that make claims relating to wrinkle repair or skin regeneration. 

For importers, this distinction has significant compliance implications. Products regulated as drugs may be subject to additional FDA requirements that do not apply to conventional cosmetics. Before arranging production or shipment, businesses should carefully review product claims, labeling, and marketing materials to determine whether the intended use places the product within the cosmetic framework or another FDA regulatory category.

Understanding what legally qualifies as a cosmetic is the first step in the import process because the definition determines which regulatory obligations apply throughout the product’s lifecycle.

The MoCRA Regulatory Framework

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) represents the most significant reform of U.S. cosmetic regulation in decades. Prior to its enactment, many aspects of cosmetic registration operated through voluntary programs, and FDA enforcement powers were comparatively limited. MoCRA introduced mandatory regulatory obligations designed to strengthen consumer protection and improve FDA oversight of cosmetic products distributed in the United States. 

What Changed with MoCRA

MoCRA transformed cosmetic regulation by introducing mandatory facility registration, cosmetic product listing, safety substantiation, serious adverse event reporting, and expanded FDA enforcement authority. Manufacturers and processors that fall within the scope of the legislation must now satisfy these requirements as part of their ongoing compliance responsibilities rather than relying on voluntary participation. 

The End of VCRP

One of the first practical changes under MoCRA was the end of the Voluntary Cosmetic Registration Program (VCRP). The VCRP officially concluded in March 2023, and companies can no longer rely on previous voluntary registrations to demonstrate compliance. Mandatory submissions are now made through FDA’s new regulatory framework using the Cosmetics Direct electronic portal. 

FDA’s Expanded Authority

MoCRA also significantly expanded the FDA’s authority. The agency can now require safety substantiation records, receive mandatory reports of serious adverse events, access certain records during investigations, and order mandatory recalls when qualifying cosmetic products present a reasonable probability of causing serious adverse health consequences. These powers extend FDA oversight well beyond the point of importation and into the ongoing commercial life of cosmetic products. 

Section 607 of the FD&C Act

Section 607 of the FD&C Act provides the statutory authority for facility registration and product listing under MoCRA. It establishes who must register, what information must be submitted, applicable timelines, and the continuing obligation to maintain accurate registration information. These provisions form the administrative foundation of the modern cosmetic regulatory system. 

Timeline of Implementation

MoCRA has been implemented in stages since its enactment. One of the most significant milestones is the first biennial facility registration renewal deadline of July 1, 2026. Facilities that registered by December 29, 2023 must complete their first renewal by this date and continue renewing every two years thereafter. This deadline has become a major compliance priority for manufacturers and processors supplying cosmetics to the U.S. market. 

Understanding the MoCRA framework provides the regulatory foundation for importing cosmetics into the United States. The next step is examining who must register their facilities, how registration is completed, and what ongoing obligations manufacturers and processors must meet under the new law. 

MoCRA Facility Registration

One of the most significant compliance obligations introduced by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) is mandatory facility registration. While importers often focus on customs documentation and tariff classification, FDA facility registration is equally important for many businesses involved in manufacturing or processing cosmetic products intended for the U.S. market. Registration enables the FDA to identify where cosmetic products are manufactured, communicate with regulated facilities, conduct inspections, and respond more effectively to public health concerns. It is important to note that FDA facility registration and CBP customs entry are separate requirements, meeting one does not satisfy the other. 

Who Must Register

Under Section 607 of the FD&C Act, owners or operators of facilities that manufacture or process cosmetic products for distribution in the United States are generally required to register with the FDA. This applies to both domestic facilities and qualifying foreign manufacturing sites that export cosmetics into the U.S. market. The requirement is tied to the activities performed at the facility rather than the ownership of the cosmetic brand itself. For example, a contract manufacturer producing cosmetics for multiple private-label brands may still be required to register because it performs manufacturing or processing activities.

Not every business in the supply chain is subject to registration. Companies that solely distribute finished cosmetic products without manufacturing or processing them should evaluate their specific role to determine whether registration applies. Likewise, businesses should carefully review whether any statutory exemptions apply before assuming they are outside the scope of MoCRA. 

Form FDA 5066 and Cosmetics Direct

Facility registrations are submitted electronically through FDA’s Cosmetics Direct portal using Form FDA 5066. This portal serves as the FDA’s centralized platform for submitting new registrations, updating existing information, and completing future renewal requirements. The transition to an electronic submission system replaces the former voluntary registration process and creates a standardized method for maintaining facility information. 

Before beginning the registration process, businesses should gather all required facility information, including ownership details, contact information, physical address, and applicable facility identifiers. Maintaining accurate registration records is an ongoing obligation, and companies should establish internal procedures to review and update information whenever changes occur.

FDA Establishment Identifier (FEI)

A key prerequisite for facility registration is obtaining an FDA Establishment Identifier (FEI). The FEI is a unique number assigned by the FDA to identify a manufacturing or processing establishment. Rather than identifying individual products, the FEI identifies the physical facility responsible for regulated activities.

The FEI plays an important role throughout the MoCRA framework because it links facilities to product listings and other regulatory records maintained by the FDA. Businesses planning to enter the U.S. market should obtain their FEI well before scheduling commercial shipments to avoid unnecessary delays in the registration process. Importers working with overseas manufacturers should also verify that qualifying production facilities have obtained the necessary FEI before products are exported. 

Registration Data Elements

Facility registration requires the submission of specific information that enables the FDA to identify the establishment and the parties responsible for its operation. Required information generally includes the facility’s legal name, physical address, ownership and operator details, contact information, FEI, and other information specified under Section 607 of the FD&C Act. 

Accuracy is critical. Outdated or incorrect registration information can create unnecessary compliance issues, delay regulatory communications, or complicate FDA inspections. Companies should incorporate periodic reviews into their compliance programs to ensure registration information remains current throughout the life of the facility.

Foreign Facility U.S. Agent

Foreign facilities that are required to register under MoCRA must designate a U.S. Agent. The U.S. Agent serves as the FDA’s domestic point of contact for communications relating to the registered foreign establishment, including inspections, regulatory inquiries, and official correspondence. 

Appointing a U.S. Agent does not transfer regulatory responsibility away from the foreign manufacturer. The facility remains responsible for complying with FDA requirements, maintaining accurate registration information, and responding to agency requests. However, selecting a knowledgeable and responsive U.S. Agent can significantly improve communication with the FDA and help resolve regulatory matters efficiently.

Small Business Exemption

MoCRA includes a small business exemption for certain businesses whose average gross annual cosmetic sales fall below the statutory threshold, currently identified in the brief as $1 million. However, this exemption is not universal. Certain higher-risk cosmetic categories remain subject to MoCRA requirements regardless of business size. These include products that contact the eye’s mucus membrane, products intended for internal use, injectable cosmetics, and products intended to alter appearance for more than 24 hours. 

Businesses should therefore evaluate both their annual sales and the types of products they manufacture before determining whether the exemption applies. Relying solely on revenue without considering product categories may lead to incorrect compliance decisions.

MoCRA Product Listing

Facility registration identifies where cosmetic products are manufactured or processed. Product listing identifies what cosmetic products are being marketed in the United States. Together, these two requirements form the administrative backbone of MoCRA compliance. Completing one does not satisfy the other, and qualifying businesses may need to comply with both simultaneously. 

The Responsible Person

MoCRA requires cosmetic products to be listed by the Responsible Person, generally defined as the manufacturer, packer, or distributor whose name appears on the product label. The Responsible Person is responsible for submitting product information, maintaining accurate listings, and ensuring updates are made when required. This role also connects with other MoCRA obligations, including safety substantiation and adverse event reporting. 

Form FDA 5067 and Structured Product Labeling (SPL)

Product listings are submitted electronically through Cosmetics Direct using Form FDA 5067 and the FDA’s Structured Product Labeling (SPL) format. The standardized electronic format enables consistent processing of product information and simplifies future updates as product portfolios evolve. 

Ingredient Disclosure, Timelines, and FEI Linkage

Product listings include ingredient information and other required product details specified by the FDA. New cosmetic products generally must be listed within 120 days of marketing, changes must generally be submitted within 60 days, and listings are subject to annual updates to keep FDA records current. Each listing is also linked to the manufacturing facility through its FDA Establishment Identifier (FEI), allowing the FDA to associate products with the establishments responsible for their manufacture or processing. 

The July 1, 2026 First Renewal Deadline

One of the most important implementation milestones under MoCRA is the first biennial facility registration renewal deadline of July 1, 2026. Facilities that completed their initial registrations by December 29, 2023, must renew their registrations by this deadline and continue renewing every two years thereafter. 

Businesses should not view renewal as a simple administrative exercise. Registration information should be reviewed carefully to ensure facility details remain accurate, any changes have been reported, and FDA records reflect the current status of the establishment. Waiting until the last minute or assuming an initial registration remains valid indefinitely are common compliance mistakes highlighted in the brief. Missing the renewal deadline may create unnecessary regulatory complications for businesses supplying cosmetics to the U.S. market. 

With facility registration, product listing, and renewal obligations addressed, the next stage of MoCRA compliance focuses on ongoing post-market responsibilities, including safety substantiation, serious adverse event reporting, FDA recordkeeping, and mandatory recall authority, requirements that continue long after a shipment has successfully cleared customs. 

Safety Substantiation and Adverse Event Reporting

Facility registration and product listing establish the administrative foundation of MoCRA compliance, but they are only part of the regulatory framework. Once a cosmetic product is placed on the U.S. market, manufacturers, importers, and Responsible Persons have continuing obligations to demonstrate product safety, monitor post-market performance, maintain regulatory records, and respond appropriately if serious safety concerns arise.

These post-market requirements represent one of the most significant changes introduced by the Modernization of Cosmetics Regulation Act of 2022. Unlike the previous regulatory framework, which relied heavily on voluntary industry practices, MoCRA requires businesses to maintain documented evidence supporting product safety and provides the FDA with greater authority to oversee products after they enter commerce. 

Safety Substantiation Records

MoCRA requires every cosmetic product marketed in the United States to have adequate safety substantiation. In practical terms, this means the Responsible Person must possess records demonstrating that the cosmetic is safe under its intended conditions of use or under customary conditions of use described in the product labeling. 

The legislation does not prescribe a single testing methodology or certification process. Instead, businesses are expected to maintain scientific evidence appropriate for the product they market. Depending on the formulation and intended use, this may include toxicological assessments, microbiological testing, stability studies, preservative efficacy testing, ingredient safety evaluations, published scientific literature, clinical testing, or documented risk assessments.

Importers should not assume that overseas manufacturers automatically maintain the level of documentation expected under U.S. regulations. Before importing products commercially, businesses should confirm that appropriate safety substantiation exists and can be produced if requested by the FDA. Maintaining these records also supports internal quality assurance and helps businesses respond efficiently to customer complaints or regulatory inquiries.

Serious Adverse Event Reporting

MoCRA also introduced mandatory reporting requirements for serious adverse events associated with cosmetic products.

When the Responsible Person becomes aware of a reportable serious adverse event, it must generally be reported to the FDA within 15 business days. The report must contain the information required by the agency, and businesses are expected to maintain supporting records relating to the incident. 

To comply with this obligation, companies should establish internal procedures for collecting, evaluating, documenting, and escalating consumer complaints. Customer service teams, distributors, retailers, and e-commerce partners should understand how complaints are identified and when they require regulatory review. A centralized complaint management process can help ensure potentially reportable events are not overlooked.

FDA Records Access and Mandatory Recall Authority

MoCRA expanded the FDA’s authority to access records relating to cosmetic products when the agency has reason to believe a product presents a safety concern. Businesses should therefore maintain organized documentation supporting safety substantiation and other regulatory obligations so that information can be produced promptly when requested. 

The legislation also grants the FDA mandatory recall authority for cosmetics. If a cosmetic product presents a reasonable probability of causing serious adverse health consequences and the responsible party fails to conduct an appropriate voluntary recall, the FDA now has the authority to order the product’s removal from the marketplace. This represents a significant expansion of FDA enforcement powers and reinforces the importance of robust quality assurance, traceability, and recall procedures throughout the supply chain. 

HTSUS Classification for Cosmetics

While FDA compliance determines whether a cosmetic product may be legally marketed in the United States, U.S. Customs and Border Protection (CBP) determines how that product is classified for customs purposes. Correct classification under the Harmonized Tariff Schedule of the United States (HTSUS) affects duty rates, customs documentation, trade program eligibility, and regulatory reporting. Misclassification can result in shipment delays, additional duties, penalties, or customs audits, making tariff classification one of the most important responsibilities for cosmetic importers. 

HTS 3303 – Perfumes and Toilet Waters

Heading 3303 covers perfumes and toilet waters. Products classified under this heading are generally fragrance products intended to impart scent rather than provide therapeutic benefits. Correct classification depends on the product’s composition and intended use, and supporting documentation should accurately describe the product being imported. 

HTS 3304 – Beauty, Make-Up, and Skin Care Preparations

Heading 3304 includes a broad range of beauty and skin care products such as facial creams, moisturizers, foundations, powders, lipsticks, eye makeup, manicure and pedicure preparations, and other cosmetic preparations designed to improve appearance. Because this heading encompasses many of the products most commonly imported by beauty brands, importers should review tariff classifications carefully before filing customs entries. 

HTS 3305 – Hair Care Preparations

Hair care products generally fall under HTS 3305. This heading includes shampoos, conditioners, hair sprays, styling preparations, and similar cosmetic products intended for hair care. However, products making therapeutic claims, such as certain anti-dandruff shampoos, may fall under different FDA regulatory requirements despite their customs classification. 

HTS 3306 – Oral and Dental Preparations

Products such as toothpaste, mouthwash, and other oral hygiene preparations are generally classified under HTS 3306. Importers should remember that while customs classification is based on the HTSUS, certain oral care products—such as fluoride toothpaste—may also be regulated as drugs by the FDA because of their intended use. 

HTS 3307 – Deodorants, Bath Preparations, and Other Cosmetic Products

Heading 3307 covers deodorants, shaving preparations, bath products, depilatories, and various other cosmetic preparations that are not classified elsewhere within Chapter 33. Importers should ensure that product descriptions on commercial invoices accurately reflect the products being imported to support proper customs classification. 

HTS 3401 – Soaps and Cleansing Bars

Although many personal care products fall under Chapter 33, certain soaps and cleansing bars are classified under HTS 3401. Whether a cleansing product belongs in Chapter 33 or Chapter 34 depends on its composition and tariff classification rules. Businesses should avoid assuming that all cleansing products are classified identically, particularly when importing large product portfolios with different formulations. 

Duty and Tariff Treatment for Imported Cosmetics

After determining the correct HTSUS classification, importers must understand the duties, tariffs, and fees that apply to cosmetic products entering the United States. Landed cost is influenced not only by the base duty rate but also by additional trade measures, preferential trade agreements, and customs processing fees. Evaluating these factors before shipment helps businesses estimate import costs accurately and avoid unexpected expenses at the border. 

Most-Favored-Nation (MFN) Duty Rates

Most cosmetic products imported into the United States are subject to Most-Favored-Nation (MFN) duty rates established under the HTSUS. The applicable rate depends on the product’s tariff classification, making accurate classification essential for determining total import costs. 

Section 301 Tariffs and the Section 122 Bridge Tariff

Certain cosmetic products imported from specific countries may also be subject to additional trade measures, including Section 301 tariffs. The brief also references the Section 122 bridge tariff, emphasizing the importance of reviewing current trade measures that may affect imported cosmetics depending on their country of origin. Importers should evaluate these additional duties when calculating landed costs and sourcing decisions. 

USMCA, Merchandise Processing Fee, and the Post-Section 321 Environment

Products that qualify under the United States-Mexico-Canada Agreement (USMCA) may benefit from preferential tariff treatment when they satisfy the agreement’s rules of origin. Importers should also account for the Merchandise Processing Fee (MPF), which applies to many commercial entries and forms part of the overall landed cost calculation. Finally, businesses should understand the evolving post-Section 321 environment, particularly those operating cross-border e-commerce models that previously relied on de minimis entry strategies. These developments can significantly influence sourcing decisions, fulfillment strategies, and overall import costs. 

Successfully importing cosmetics requires both regulatory compliance and accurate customs classification. However, some personal care products occupy a unique regulatory space because they may be considered both cosmetics and drugs. Understanding where that boundary exists is critical, particularly for products such as sunscreens, anti-aging creams, antiperspirants, and medicated shampoos, which are discussed in the next section. 

Sunscreens, Anti-Aging, and the Cosmetic-Drug Boundary

One of the most common compliance mistakes made by cosmetic importers is assuming that all personal care products are regulated solely as cosmetics. Under U.S. law, a product’s regulatory status depends primarily on its intended use, not simply its ingredients or where it is sold. As a result, products that appear to be cosmetics may instead be regulated as over-the-counter (OTC) drugs, or in some cases, as both a cosmetic and a drug. Understanding this distinction is critical because products regulated as drugs are subject to additional FDA requirements beyond those applicable to conventional cosmetics. 

Sunscreens and the OTC Drug Monograph

Sunscreens are one of the most well-known examples of products that are regulated as drugs in the United States. Although consumers purchase them alongside moisturizers and other skincare products, sunscreens are intended to protect against ultraviolet (UV) radiation and help prevent sunburn. Because these are disease-prevention claims, sunscreens fall under the FDA’s OTC drug regulatory framework rather than being regulated solely as cosmetics. 

Importers bringing sunscreen products into the United States should recognize that compliance extends beyond MoCRA. Depending on the product, manufacturers may also need to comply with applicable OTC drug requirements relating to formulation, labeling, and manufacturing. Businesses entering the U.S. market should therefore confirm the product’s regulatory classification before production begins rather than after shipments are already in transit.

Anti-Dandruff Shampoos, Antiperspirants, and Fluoride Toothpaste

Several other everyday personal care products are also regulated as drugs because of their intended use. These include:

While these products may resemble conventional cosmetics from a consumer perspective, their therapeutic claims place them within a different FDA regulatory framework. Importers should avoid assuming that products sold in the beauty aisle automatically qualify as cosmetics under U.S. law. 

Anti-Aging Claims

Anti-aging products present another area where businesses frequently encounter compliance challenges. A facial cream promoted to moisturize, soften, or improve the appearance of skin generally remains a cosmetic. However, marketing claims suggesting that the product repairs skin damage, rebuilds collagen, regenerates cells, or alters the structure or function of the skin may cause the product to be regulated as a drug. 

This distinction extends beyond the wording printed on the product label. FDA may also consider claims made on company websites, online marketplaces, advertising materials, social media content, and promotional brochures when determining a product’s intended use.

Intended Use Determines Regulation

The FDA consistently evaluates products based on intended use rather than marketing category or ingredient list alone. This means businesses should review all consumer-facing materials before launching products in the United States to ensure that claims accurately reflect the intended regulatory pathway. 

For importers, regulatory review should occur during product development rather than after customs documentation has been prepared. Early evaluation reduces the likelihood of shipment delays, product relabeling, or enforcement actions that may arise from inappropriate product claims.

State-Level Compliance Beyond FDA

While FDA regulations apply nationwide, cosmetic importers should also be aware that individual states may impose additional compliance requirements. A product that satisfies federal requirements may still be subject to state-specific ingredient restrictions, labeling obligations, or consumer notification requirements. Businesses distributing products across multiple states should therefore develop compliance strategies that consider both federal and state regulations. 

California Proposition 65

One of the most recognized state requirements affecting cosmetic products is California Proposition 65. The law requires businesses to provide warnings when consumers may be exposed to chemicals identified by the state as causing cancer, birth defects, or other reproductive harm. Depending on a product’s formulation, Proposition 65 warning requirements may apply even when the product fully complies with FDA regulations. 

California Safe Cosmetics Act

California also maintains the California Safe Cosmetics Act, which establishes additional reporting obligations relating to certain cosmetic ingredients. Businesses marketing products within California should evaluate whether any ingredients in their formulations trigger state-specific reporting or disclosure requirements beyond those imposed at the federal level. 

Fragrance Allergens and Emerging State Rules

Several states continue to introduce legislation addressing cosmetic ingredients, fragrance allergens, and substances of concern. As state requirements evolve, businesses distributing products nationally should monitor legislative developments to ensure continued compliance. Failure to account for changing state regulations may result in additional compliance costs or restrictions on product sales within particular jurisdictions. 

Developing a Multi-State Compliance Strategy

Rather than creating separate formulations for different markets, many businesses choose to develop products that satisfy the most stringent applicable requirements. This approach can simplify inventory management, reduce regulatory complexity, and improve consistency across national distribution channels. The brief emphasizes the importance of monitoring both FDA requirements and state-level developments when establishing long-term compliance programs. 

The CBP Customs Clearance Process

FDA compliance alone does not permit cosmetics to enter the United States. Every commercial shipment must also satisfy the customs requirements administered by U.S. Customs and Border Protection (CBP). Successful customs clearance depends on accurate documentation, proper tariff classification, and compliance with both customs and FDA import procedures. Importers that prepare documentation carefully before shipment can significantly reduce the likelihood of delays at the border. 

Commercial Invoice and HTSUS Declaration

The commercial invoice is one of the primary documents reviewed during customs clearance. It should accurately describe the imported products, identify the seller and purchaser, state the customs value, and include the appropriate HTSUS classification. Accurate product descriptions and tariff classifications help CBP assess duties correctly and facilitate efficient processing. 

Country of Origin Marking

Imported cosmetic products must also comply with applicable country of origin marking requirements. Proper origin declarations enable CBP to determine the correct duty treatment and support the administration of trade agreements and trade remedy measures. Importers should verify that origin markings are accurate and consistent with customs documentation before shipment. 

ACE Filing and FDA Coordination

Commercial entries are processed electronically through CBP’s Automated Commercial Environment (ACE). Depending on the product, FDA information may also be transmitted through the same electronic entry process, allowing the two agencies to coordinate review of imported cosmetic shipments. Accurate electronic filing reduces processing delays and supports more efficient customs clearance. 

Joint CBP/FDA Enforcement

Although CBP and the FDA perform different regulatory functions, they work together to review imported cosmetic products. CBP evaluates customs admissibility and tariff compliance, while the FDA assesses whether products meet applicable health and safety requirements. Shipments that raise concerns may be held for additional examination until both agencies are satisfied that the products comply with applicable regulations. 

Successfully clearing customs is only one milestone in the import process. Importers must also understand the practical differences between personal-use and commercial imports, the unique compliance considerations associated with e-commerce and Amazon sales, and the circumstances that may lead to FDA import alerts or border refusals. These topics are covered in the final section of this guide. 

Personal Use Versus Commercial Import

Not every cosmetic product entering the United States is subject to the same regulatory requirements. The FDA distinguishes between products imported for personal use and those imported for commercial distribution, and the obligations imposed on importers vary significantly depending on the intended purpose of the shipment. Businesses should understand this distinction because a shipment initially described as personal use may be treated as a commercial import if the quantity, frequency, or surrounding circumstances indicate that the products are intended for resale. 

Personal Use Imports

The FDA generally exercises enforcement discretion for cosmetics imported solely for an individual’s personal use. The brief notes that personal-use imports are commonly associated with quantities representing approximately a 90-day personal supply, provided there is no indication that the products are intended for commercial sale. These shipments are evaluated differently from commercial imports and typically do not trigger the full range of MoCRA compliance obligations applicable to products entering U.S. commerce. 

When a Personal Import Becomes Commercial

The distinction between personal and commercial importation is based on more than quantity alone. Customs authorities may also consider factors such as the frequency of shipments, the variety of products imported, packaging, and evidence suggesting resale or distribution. Once a shipment is determined to be commercial in nature, the importer is expected to comply with all applicable FDA and CBP requirements, including those relating to facility registration, product listing, customs classification, and import documentation. Businesses should therefore avoid relying on repeated personal-use shipments as a substitute for commercial compliance. 

E-commerce, Amazon U.S., and Direct-to-Consumer (DTC) Considerations

The rapid growth of cross-border e-commerce has made it easier than ever for international beauty brands to reach U.S. consumers. Whether products are sold through Amazon, a brand’s own website, or another online marketplace, cosmetics imported for commercial sale remain subject to the same FDA and customs requirements as products distributed through traditional retail channels. Selling online does not exempt businesses from MoCRA compliance or CBP import procedures. 

Amazon Seller and Foreign Brand Considerations

Foreign brands entering the U.S. market through Amazon or other e-commerce platforms should establish their regulatory responsibilities before launching products. Depending on the business model, this may include identifying the appropriate Responsible Person, ensuring qualifying manufacturing facilities are registered, completing required product listings, and maintaining safety substantiation records. Importers should also verify that product labeling and marketing claims remain consistent with FDA requirements across all online sales channels. 

Landed Cost After Section 321 Changes

The brief also highlights the importance of understanding the evolving post-Section 321 environment for cross-border e-commerce. Businesses that previously relied on de minimis entry strategies should carefully evaluate current customs requirements when calculating landed costs and designing their U.S. fulfillment strategies. A thorough understanding of customs duties, processing fees, and applicable trade measures is essential for maintaining competitive pricing while remaining fully compliant with U.S. import regulations. 

FDA Import Alerts and Border Refusals

Even when customs documentation has been prepared correctly, cosmetic shipments may still be delayed or refused if FDA compliance concerns arise. The FDA works closely with U.S. Customs and Border Protection to review imported cosmetic products and may take enforcement action when products appear to violate applicable laws or present potential risks to consumers. Understanding how import alerts operate can help businesses reduce the likelihood of costly shipment disruptions. 

Common Reasons for Detention

Cosmetic shipments may be detained for a variety of reasons, including labeling deficiencies, products that appear to be adulterated or misbranded, unsupported product claims, or other indications that the products do not comply with applicable FDA requirements. Documentation inconsistencies between customs declarations and product information may also contribute to additional scrutiny at the border. 

Detention Without Physical Examination (DWPE)

The FDA may place certain products or manufacturers on an Import Alert, allowing shipments to be detained without physical examination when previous compliance concerns indicate an increased risk of violations. Importers should monitor applicable Import Alerts and work proactively with manufacturers to address recurring compliance issues before products are shipped to the United States. 

Responding to FDA Detention

If a shipment is detained, importers should respond promptly to FDA requests and provide supporting documentation demonstrating that the products comply with applicable regulatory requirements. Depending on the circumstances, this may include labeling information, safety documentation, manufacturing records, or other evidence requested by the agency. Preparing comprehensive compliance documentation before shipment can significantly improve an importer’s ability to respond efficiently if questions arise during the import review process. 

Frequently Asked Questions

Do imported cosmetics need FDA approval before they are sold?

No. Conventional cosmetics generally do not require premarket FDA approval. However, they must comply with the applicable requirements of the FD&C Act and MoCRA before they are marketed in the United States. 

Do foreign cosmetic manufacturers need to register with the FDA?

If they manufacture or process cosmetic products for distribution in the United States and are subject to MoCRA, qualifying foreign facilities are generally required to register and designate a U.S. Agent. 

Who is the Responsible Person under MoCRA?

The Responsible Person is generally the manufacturer, packer, or distributor whose name appears on the product label and is responsible for product listing and several ongoing compliance obligations. 

Does MoCRA apply to small businesses?

Certain small businesses may qualify for an exemption based on annual cosmetic sales, but important exceptions apply for specified higher-risk product categories. 

Can I import cosmetics for personal use?

Yes. The FDA generally exercises enforcement discretion for products imported solely for personal use, typically involving quantities consistent with approximately a 90-day personal supply. 

How often must facility registrations be renewed?

Facility registrations are renewed every two years, with the first renewal deadline for qualifying facilities falling on July 1, 2026. 

What happens if my cosmetic shipment is detained?

Importers should review the FDA’s detention notice carefully and provide the documentation requested by the agency to demonstrate compliance. 

How do I know the correct HTSUS classification for my cosmetic?

Classification depends on the product’s composition and intended use. Importers should review the applicable HTSUS headings and supporting customs guidance before filing an entry. 

Bringing It Together

Importing cosmetics into the United States now requires a coordinated understanding of both FDA regulatory compliance and U.S. customs procedures. From determining whether a product qualifies as a cosmetic to completing facility registration, product listing, customs classification, and post-market compliance under MoCRA, every stage of the import process plays a role in ensuring products enter the U.S. market efficiently and lawfully. Businesses that build compliance into their supply chain before products are shipped are better positioned to avoid costly delays, regulatory enforcement, and unnecessary disruptions.

If your business imports cosmetics or personal care products into the United States, working with an experienced customs broker can help you navigate both CBP import requirements and the broader regulatory landscape. Proper planning before shipment remains the most effective strategy for achieving smooth customs clearance and maintaining long-term compliance.